Table 3

Comparing baseline characteristics of patients with and without active disease (DAS>2.4) after 3 months of induction DMARD treatment

Active disease
Yes (n=42)No (n=78)p Value
Age (years), median (IQR)55 (45–63)54 (43–64)0.69
Sex, female, no (%)35 (83)43 (55)0.002
Symptom duration (days), median (IQR)139 (92–208)164 (116–214)0.30
RF positive, no (%)24 (57)54 (69)0.19
ACPA positive, no (%)27 (64)57 (73)0.31
Morning stiffness >1 h, no (%)33 (79)60 (77)0.84
Erosion, no (%)4 (10)16 (21)0.12
Fulfilment of RA criteria, no (%)
 198728 (67)54 (69)0.77
 201042 (100)72 (92)0.07
DAS, mean (95% CI)3.89 (3.65 to 4.14)3.17 (3.02 to 3.34)<0.0001
TJC44, median (IQR)14 (10–21)7 (3–14)<0.0001
SJC44, median (IQR)8.5 (4–12)8 (4–12)0.95
ESR (mm/h), median (IQR)29 (17–45)20 (12–34)0.03
General health (0–100 mm), median (IQR)54 (50–70)51.5 (30–65)0.02
Treatment, no (%)
 A. MTX+SSZ+HCQ+GCs IM11 (26)32 (41)0.11
 B. MTX+SSZ+HCQ+GCs oral10 (24)29 (37)0.14
 C. MTX+GCs oral21 (50)17 (22)0.002
  • ACPA, anti-citrullinated peptide antibodies; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HCQ, hydroxychloroquine; IM, intramuscular; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC44, swollen joint count (44 joints); SSZ, sulfasalazine; TJC44, tender joint count (44 joints).